The International Journal of Neuropsychopharmacology



Letter to the Editor

Lithium response and −116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder


Chihiro Kakiuchi a1 and Tadafumi Kato a1c1
a1 Laboratory for Molecular Dynamics of Mental Disorders, Brain Science Institute, RIKEN, Wako-shi, Saitama 351-0198, Japan

Article author query
kakiuchi c   [PubMed][Google Scholar] 
kato t   [PubMed][Google Scholar] 

Three mood stabilizers, lithium, valproate and carbamazepine, are known to be effective for a subset of patients with bipolar disorder, but the mechanism(s) of action for these three drugs is controversial (Gray et al., 2003). The response to treatment varies among individuals, but to date, no biological marker for predicting treatment response has been identified (Ikeda and Kato, 2003). Several groups have been pursuing a genetic marker that can be used to predict treatment response to lithium. Several polymorphisms of the genes such as serotonin transporter (Del Zompo et al., 1999; Serretti et al. 2001), tryptophan hydroxylase (Serretti et al., 1999) and inositol polyphosphate 1-phosphatase (Steen et al., 1998), have been suggested to relate to the lithium response, but these findings are still controversial. Thus, clinicians select mood stabilizers only empirically.

(Received September 28 2004)
(Reviewed November 16 2004)
(Revised December 21 2004)
(Accepted December 26 2004)


Correspondence:
c1 Laboratory for Molecular Dynamics of Mental Disorders, Brain Science Institute, RIKEN, Hirosawa 2-1, Wako, Saitama, 351-0198, Japan. Tel.: +81-48-467-6949 Fax: +81-48-467-6947 E-mail: kato@brain.riken.jp